The U.S. FDA cleared Medtronic’s Hugo robotic-assisted surgery (RAS) system and CMR Surgical’s Versius Plus system, expanding the pool of cleared robotic platforms for soft-tissue procedures. The approvals give hospitals additional procurement choices amid rising demand for robotic-assisted surgeries and the dominance of incumbent vendors. New market entrants may pressure pricing, service contracts, and purchasing decisions at health systems. For manufacturers and surgical device investors, the clearances validate alternative designs and may accelerate adoption where hospitals seek competition to the largest incumbent’s offerings.